Agreed, and a "buyout" is something that may not come for years. A licensing agreement for Kevetrin ($5 billion annual potential) and Prurisol ($500 million-$1 billion annually) is a nice cash-cow for LEO and Dr Menon to oversee until they get "overwhelmed" with a buyout offer. Dr Menon is chiefly a scientist, and he wants to keep working on his other compounds...there is no rush on a buyout . . . which will make CTIX even that more valuable!